Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi AventisfiledCriticalSanofi Aventis
Publication of HN2010000388ApublicationCriticalpatent/HN2010000388A/en
102100031658C-X-C chemokine receptor type 5Human genes0.000abstract3
101000922405Homo sapiens C-X-C chemokine receptor type 5Proteins0.000abstract3
208000037265diseases, disorders, signs and symptomsDiseases0.000abstract2
201000010099diseaseDiseases0.000abstract1
Landscapes
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A ANTICUERPOS HUMANIZADOR QUE SE UNEN ESPECIFICAMENTE A CXCR5 Y, POR EJEMPLO, PUEDEN INHIBIR LA FUNCION DE CXCR5. LA INVENCION TAMBIEN INCLUYE USOS DE LOS ANTICUERPOS PARA TRATAR O PREVENIR ENFERMEDADES O TRASTORNOS RELACIONADOS CON CXCR5.THIS INVENTION REFERS TO HUMANIZING ANTIBODIES THAT SPECIFICALLY JOIN CXCR5 AND, FOR EXAMPLE, MAY INHIBIT THE CXCR5 FUNCTION. THE INVENTION ALSO INCLUDES USES OF THE ANTIBODIES TO TREAT OR PREVENT DISEASES OR DISORDERS RELATED TO CXCR5.
HN2010000388A2007-08-292010-02-26
ANTI-CXCR5 HUMANIZED ANTIBODIES, DERIVED FROM THE SAME AND ITS USE
HN2010000388A
(en)